Regulatory milestones

ALK-Abello A/S (CSE:ALK-B) gained DKK35 to DKK617 last week after FDA's Allergenic Products Advisory Committee unanimously voted that available data support the efficacy of Grastek grass Allergy Immunotherapy Tablet (AIT) to treat Timothy grass pollen induced allergic rhinitis, with or without conjunctivitis, in individuals five years of age and older.